OUR SOLUTIONS / VASOSPASM

Take command
in vasospasm

COMANECI™ is the only active assist device with the versatility to treat wide-neck aneurysms and restore arteries in vasospasm, providing results without permanent implants.

OUR SOLUTIONS / VASOSPASM

Take command
in vasospasm

COMANECI™ is the only active assist device with the versatility to treat wide-neck aneurysms and restore arteries in vasospasm, providing results without permanent implants.

Cerebral vasospasm is an orphan disease, and leading cause of death and disability following subarachnoid haemorrhage (SAH) 1,2 , yet lacks a defined treatment strategy.

COMANECI is the first device to receive FDA breakthrough designation to provide options for these patients.

Strokes in smaller arteries can still cause disabling deficits, and clot-dissolving drugs work less than half the time.1,2,3


Yet, these vessels are at increased risk for hemorrhage during treatment.

Restore the flow with active control

Unlike other angioplasty devices, COMANECI’s active technology offers precise control over vessel dilation with full visibility, potentially reducing the risk of vessel injury. 1,2 

Gradual expansion can achieve similar results as high-impact balloons–with less damage to the vessel. 3 

Continuous blood supply

Unlike balloons, COMANECI provides support without blocking blood flow to the brain. Clinicians can focus on accurate placement rather than the countdown to an

ischemic event.

COMANECI demonstrates the highest complete occlusion and lowest complication rates. 

See the comparison

Enable

combination

therapy

The patent design of COMANECI allows dual treatment—mechanical dilation plus the concurrent

infusion of vasodilators. Synergistic action may enhance efficacy compared to a single treatment.

The proof is in

the patients

In a multicenter study, severe vessel constriction improved significantly, with 52% of patients achieving favorable outcomes at 6 months. 2

Unlock the data

The proof is in

the patients

In a multicenter study, severe vessel constriction improved significantly, with 52% of patients achieving favorable outcomes at 6 months.2

Unlock the data

Click on a tab below to learn more.

Clinical evidence
Product overview
How it works
In-Practice
Clinical evidence

PRODUCT OVERVIEW

COMANECI™ is designed with active, responsive technology to enable non-occlusive coil embolization procedures.

SPECIFICATIONS


*Not all products are available in all countries.
Place an order Ask a product question Request an IFU

HOW IT WORKS

1 TREAT distal → proximal

2 Gradually EXPAND COMANECI™

3 WAIT for dilation–on average 2.5 minutes (range 30 sec. – 5 min). 5

Place an order Ask a product question Request an IFU
Webinars banner

WEBINARS

Physician-led webinars are available to view on-demand. To watch a recording, please submit a request here.

Request to view
DR. TUFAIL PATANKAR | Romford, UK
Acomm blister aneurysm with severe vasospasm
View the case →
DR. SVETLANA RUDNICKA | Denmark | Presented at the WIFTN Congress
Single-center experience of active multisessional vasospasm treatment
View the case →
Place an order Ask a product question Request an IFU

Questions?

Reach out to learn more about our company and stroke solutions.

1. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16(4):562-572. doi:10.1161/01.str.16.4.562

2. Salem MM, Khalife J, Desai S, et al. COManeci MechANical Dilation for vasospasm (COMMAND): multicenter experience. J Neurointerv Surg. 2023;15(9):864-870. doi:10.1136/jnis-2022-019272

3. Bhogal P, Pederzani G, Grytsan A, et al. The unexplained success of stentplasty vasospasm treatment : Insights using Mechanistic Mathematical Modeling [published correction appears in Clin Neuroradiol. 2019 Dec;29(4):775. doi: 10.1007/s00062-019-00782-4.]. Clin Neuroradiol. 2019;29(4):763-774. doi:10.1007/s00062-019-00776-2

4. Data on file

5. Hensler J, Larsen N, Wodarg F, et al. P099 Multi-center study to assess effectiveness of the comaneci device in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH)- interim results. Journal of NeuroInterventional Surgery 2024;16:A88.